E-Newsletter
June 2016

NEWS

GlaxoSmithKline plans to file NDA in U.S. for FF/UMEC/VI in patients with COPD

GlaxoSmithKline plc and Innoviva, Inc announced that, following discussions with the US FDA ,GSK has brought forward the plan to file a NDA in the US for the once-daily closed triple combination therapy, fluticasone.

Merck Inc and the GIZ Cooperate in Africa

Merck, a leading science and technology company, today announced that it signed a letter of intent on innovation and digitalization in Africa with the GIZ (Deutsche Gesellschaft für Internationale Zusammenarbeit) yesterday evening. This

Chugai set to present Alecensa's Japanese phase III results at ASCO

Chugai Pharmaceutical Co Ltd announced that the results of the Japanese phase III study (J-ALEX) of Alecensa®, in ALK fusion gene positive non-small cell lung cancer (NSCLC) patients, will be presented at the annual meeting of the

PRESS RELEASES

Bayer collaborates with U.S. National Surgical Adjuvant Breast and Bowel Project to Investigate Stivarga as Adjuvant Therapy in Colon Cancer

Eli Lilly and Company announced today that the U.S. Food and Drug Administration (FDA) has approved Taltz (ixekizumab) injection 80 mg/mL for the treatment of moderate-to-severe plaque psoriasis in adult patients who are candidates for systemic therapy or phototherapy.

Allergan receives US FDA marketing approval for Juvederm Volbella XC for use in lips & perioral rhytids

Eli Lilly and Company and Incyte Corporation announced that detailed results of RA-BEACON - a pivotal phase 3 global study of baricitinib,.

Daiichi Sankyo Launches Antiplatelet Agent Efient® Tablets 20mg

A new guideline focused update provided oral antiplatelet therapy Effient (prasugrel) with a Class IIa recommendation,.